Standard BioTools Inc.

Standard BioTools Inc.

LABNYSE / NASDAQHealthcareSmall cap

$0.63+$0.02 (+3.3%)

Last close · Data as of Nov 20, 2026

Market cap
$495.8M
P/E
-6.6x
EV / EBITDA
-4.7x
Revenue
$85.3M
Net margin
-87.8%
ROCE
-20.3%

-50.8% over the last year

Standard BioTools Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-1.6%
3M
-3.1%
6M
-40.6%
1Y
-50.8%
5Y
-86.0%

52-week range

Day change +$0.02 (+3.3%) from $0.61 to $0.63 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in LAB, bought on each weekday since 2021.

News & filings

What Standard BioTools filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 74.9 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 4.19 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.

Read moreShow less

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Shares outstanding
386.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$495.8M
P/E
-6.6x
P/B
1.2x
EV / EBITDA
-4.7x
EV / Sales
4.8x
P/S
5.8x
52-week high
$1.68
52-week low
$0.54

Profitability

Operating margin
-109.3%
Net margin
-87.8%
EBITDA margin
-100.4%
ROE
-17.7%
ROCE
-20.3%
ROIC
-22.8%
ROA
-13.2%
Asset turnover
0.15

Growth

Revenue
$85.3M
Revenue growth, 1Y
-6.2%
Revenue CAGR, 3Y
-4.5%
Net profit growth, 1Y
-46.1%
Free cash flow
-$82.6M

Solvency

Current ratio
4.19
Debt / Equity
0.07
Debt / Assets
0.05
CFO / Net profit
0.99
Cash / Market cap
24.4%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$85.3M
Cost of revenue$42.8M
Gross profit$42.5M
Operating expenses$135.8M
Research and development$26.0M
Selling, general and administrative$109.9M
Operating income-$93.3M
Interest and other-$3.4M
Pretax income-$96.7M
Tax and other-$21.8M
Net income-$74.9M

Revenue and net profit

Revenue fell 6.2% in FY2025; net profit is the dashed line.

Standard BioTools Inc. revenue and net profit by fiscal year
Standard BioTools Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$97.9M-$190.1M
FY2023$106.3M-$74.7M
FY2024$91.0M-$138.9M
FY2025$85.3M-$74.9M

Cash flows

FY2025: -$74.3M from operations, -$82.6M free after investment (dashed).

Standard BioTools Inc. operating and free cash flow by fiscal year
Standard BioTools Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$89.4M-$93.2M
FY2023-$43.3M-$46.1M
FY2024-$143.5M-$151.8M
FY2025-$74.3M-$82.6M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$85.3M-6.2%1Y
EBITDA
-$85.7M
Net profit
-$74.9M
Cash from operations
-$74.3M
Free cash flow
-$82.6M
Revenue CAGR, 3Y
-4.5%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$85.3M-$85.7M-$74.9M-$82.6M-17.7%-6.2%-46.1%

Monthly returns

Month-by-month returns of LAB across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$567.8M
Liabilities$143.5M
Equity$424.3M
Paid-in capital$1.7B
Retained earnings-$1.3B
Treasury stock$46.5M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; LAB highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. CTEV5.3x
  2. Standard BioTools Inc. (this company)4.8x

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Standard BioTools Inc.LABthis company$495.8M-6.6x1.2x-17.7%-4.7x
Aquestive Therapeutics, Inc.AQST$519.4M-6.2x-15.4x248.9%-6.7x
Pacific Biosciences of California, Inc.PACB$506.3M-0.9x94.6x-10214.5%-7.5x
Arvinas, Inc.ARVN$499.4M-6.2x1.2x-18.6%-3.2x
AngioDynamics, Inc.ANGO$497.1M-14.6x2.7x-18.6%256.3x
Evolent Health, Inc.EVH$492.7M-0.9x1.2x-128.7%-3.7x
Prothena Corporation plcPRTA$484.3M-2.0x1.7x-87.0%-1.0x
The Oncology Institute, Inc.TOI$473.9M-7.8x-30.1x385.5%-12.8x
CTEVCTEV$470.0M——163.5%10.8x
Peer median—-6.2x1.2x-18.6%-3.5x

Year-to-date ROI

LAB since 1 January, against earlier years.

Historical volatility

LAB's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Standard BioTools Inc. operating margin by fiscal year
Standard BioTools Inc. operating margin by fiscal year
DateOperating margin
FY2022-104.8%
FY2023-59.3%
FY2024-95.6%
FY2025-109.3%
LineFY2025
Cost of revenueCost Of Revenue$42.8M
Gross profitGross Profit$42.5M
Operating expensesOperating Expense$135.8M
Research and developmentResearch And Development$26.0M
Selling, general and administrativeSelling General And Administration$109.9M
Total expensesTotal Expenses$178.6M
Pretax incomePretax Income-$96.7M

Learn while you research

Academy chapters picked for Standard BioTools Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →